Background: We aimed to investigate the effect of retinal vein occlusion (RVO) on the posterior segment structures of the eye and its changes with intravitreal anti-Vascular Endothelial Growth Factor (VEGF) treatment.
Methods: This prospective longitudinal study included 29 eyes of 29 patients with RVO (17 males and 12 females) followed for 6 months. The best corrected visual acuity (BCVA), macula, choroid ticknesses and choroidal vascularity index (CVI) obtained by spectral-domain optical coherence tomography were recorded at baseline and the first, third, and sixth months after the first injection. Results were compared with fellow eyes (non-affected eyes) and age- and sex-matched controls.
Results: BCVA increased significantly in the 6th month, more in the first month of injection (p < 0.05 for each). Central macular tickness, subfoveal choroid tickness, stromal and total area of choroid decreased significantly after injection (p < 0.05 for each). CVI values increased significantly, especially in the 1st month after injection (p < 0.05 for each). In eyes with Branch RVO, there was a significant decrease in the macular thickness of the occlusive areas with treatment, while there was no statistically significant change in the non-occlusive macular thickness.
Conclusion: Observation of changes in choroidal structure may be useful to assess the activity of RVO and predict the efficacy of anti-VEGF therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11608387 | PMC |
| http://dx.doi.org/10.1007/s00417-024-06562-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Machine Learning Quantification of Fluid Volume in Eyes With Retinal Vein Occlusion Treated With Aflibercept: The REVOLT Study.
J Vitreoretin Dis
December 2024
Octane Imaging Lab, Toronto, ON, Canada.
To evaluate the combined relationship between ischemia, retinal fluid, and layer thickness measurements with visual acuity (VA) outcomes in patients with retinal vein occlusion (RVO). Swept-source optical coherence tomography (OCT) data were used to assess retinal layer thickness and quantify intraretinal fluid (IRF) and subretinal fluid (SRF) using a deep learning-based, macular fluid segmentation algorithm for treatment-naïve eyes diagnosed with visual impairment resulting from central RVO (CRVO) or branch RVO (BRVO). Patients received 3 loading doses of 2 mg intravitreal aflibercept injections and were then put on a treat-and-extend regimen.
View Article and Find Full Text PDFThe influence of UV-visible light, microwave radiation, argon laser, and heating and aging processes on silicone oil utilized as intravitreal implants: Experimental exposure with clinical correlation.
PLoS One
December 2024
Division of Ophthalmology, Department of Special Surgery, Faculty of Medicine, Jordan University of Science & Technology, Irbid, Jordan.
Purpose: The emulsification of silicone oil (SO) remains poorly understood. In the present study, we investigated the physical properties of unused pharmaceutical SO samples under various conditions. Moreover, clinical correlations with the patients' SO samples were assessed.
View Article and Find Full Text PDFReal-World Outcomes After Switch From Aflibercept to Faricimab in Eyes With Diabetic Macular Edema.
Invest Ophthalmol Vis Sci
December 2024
Medical University of Vienna, Department of Ophthalmology, Vienna, Austria.
Purpose: To assess the anatomic and functional outcomes in eyes with diabetic macular edema (DME) switched from intravitreal aflibercept to faricimab in a real-world setting.
Methods: Retrospective, interventional consecutive case series. Patients with DME were switched from aflibercept to faricimab and categorized based on central subfield thickness (CST) 4 weeks after last aflibercept injection into responding DME (rDME, CST reduction >20% or CST ≤ 250 µm) and nonresponding DME (nrDME, CST unchanged or increased).
Analysis of the aqueous humor before and after the administration of faricimab in patients with nAMD.
Sci Rep
December 2024
Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
This study aimed to evaluate the changes in cytokine levels in the aqueous humor and factors of treatment resistance following intravitreal faricimab injection in treatment-naïve patients with neovascular age-related macular degeneration. A total of 32 eyes were analyzed before and after a single faricimab injection. Although the best-corrected visual acuity (BCVA) showed no significant improvement, the mean central retinal thickness decreased significantly by 73.
View Article and Find Full Text PDFUnlabelled: Diabetic macular edema (DME) is a leading cause of visual impairment and blindness among diabetic patients, its prevalence is continuing to increase worldwide. Faricimab, a bispecific antibody, represents a new generation of treatments for DME.
Purpose: This study presents an indirect comparison of the effectiveness and safety of faricimab versus other treatment options for DME.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!